New York, NY (Vocus) April 6, 2010
George Brakatselos, senior consultant in medical marketing services and expert author, recently published his 100th article for The Examiner.com. His articles have focused on medical practice marketing and keeping doctors and the general public informed of the latest in medical research.
Machias, ME (PRWEB) September 1, 2010
Primary Organic Therapy, a non-profit medical marijuana dispensary, proudly announces their selection by Maine?s Department of Health and Human Services for operation in Whitneyville to serve Washington and Hancock counties. The new facility will be located at 90 Community Drive in Sanford, and will open for business in December of 2010.
?We are pleased for the opportunity to serve the citizens of Maine by offering alternative medicinal care to the community,? says Derek Brock, founder of Primary Organic Therapy. ?Our focus is upon patient education to introduce new treatment options for a variety of ailments that may not be fully served by traditional pharmaceutical methods.?
Primary Organic Therapy will be providing more than ten different types of genetic varieties of marijuana. These varieties are commonly referred to as ?strains? and each of exhibits different medicinal properties. These different medicine types offer a wide array of treatments for depression, anxiety, insomnia, migraines, cancer, arthritic pain, glaucoma, nausea, anorexia, and mental disorders such as autism and Alzheimer?s disease.
?While we recognize that there are many pill-based treatment plans available, we have seen a large trend towards herbal and organic treatment options. We believe good American citizens are becoming aware of the adverse long-term effects of digesting manufactured medicine, and the growing list of unexpected side effects. We are pleased to be offering quality alternative medicine that can be obtained in a legal and controlled manner,? continues Mr. Brock. ?All medicine dispensed at our location will be produced under strict quality assurance and cutting-edge testing procedures to assure consistent potency and availability. We?ve carefully spent our time investigating dispensary models in other legal states and feel we have developed superior methods to provide Maine reliable care options.?
Primary Organic Therapy?s application states that a trained physician will be on site during all operating hours to provide recommendation cards for qualifying patients, and to answer patient questions. Educational materials will be freely distributed to potential patients looking to expand their treatment options. A full featured website will also be made available enabling patients to learn about currently available marijuana medicines from the privacy of their homes. In the interest of maintaining the highest level of legal compliance, Internet location technology will be utilized to restrict website access only to residents of legal medical marijuana states.
Mr. Brock finalizes, ?Together with the state of Maine we are taking bold new steps in patient care. Education, community safety, and legal compliance are our highest priorities.?
Additional information may be found at http://www.primaryorganictherapy.com
Media Contacts:
Derek Brock
info(at)primaryorganictherapy(dot)com
http://www.primaryorganictherapy.com
(888) 360-0650
###
Related Alzheimer Disease Press Releases
Jacksonville Beach, FL (Vocus) September 10, 2010
A recent analysis published in the Public Library of Science journal, PLoS Medicine, implicates pharmaceutical giant Wyeth of paying medical ghostwriters to suppress clinical evidence linking the use of synthetic hormone drugs to an increased risk of breast cancer. The analysis by Dr. Adriane J. Fugh-Berman of Georgetown University Medical Center implies that Wyeth, now owned by Pfizer, used ghostwriters to insert favorable messages into articles published in medical journals, ultimately downplaying the dangerous health risks of synthetic hormones. The documents analyzed are part of litigation by 14,000 women who claim their use of synthetic hormones led to their development of breast cancer.
?I am gratified that the truth may finally be coming to light,? said C.W. Randolph, Jr., M.D., R.Ph., ?Multiple clinical studies have linked long-term use of synthetic hormones, such as the aforementioned, to an increased risk of heart disease, cancer, and other health problems. In contrast, multiple studies have linked individualized dosing of compounded bioidentical (natural) hormone replacement therapy (BHRT) to health benefits such as a reduced risk for breast cancer, cardiovascular disease, Alzheimer?s disease, diabetes, osteoporosis, as well as improved brain and nervous system function and quality of life.?
Even after the 2002 National Institutes of Health, Women?s Health Initiative Trial (WHI) irrefutably established that synthetic hormones (such as the popularly prescribed Premarin family of products) caused the risk of breast cancer to increase 26 percent, physicians continued to prescribe these drugs putting millions of women?s lives in jeopardy. Why? ?Because they were misled by pharmaceutical-sponsored medical studies skewing the facts,? claims Randolph.
According to Dr. Randolph, a nationally recognized medical expert in the field of BHRT, this type of evidence has existed for decades.
As early as 1941, Edgar Allen, M.D., Chair of Yale Medical School Anatomy Department, published an article in the medical journal Cancer Research on the propensity of estrogen to cause cancer in animals. Since that time, the output of medical research and clinical studies continued to mount until, in 2001, representatives from the National Cancer Institute and the National Institutes of Health (NIH) voted 8-1 to add synthetic estrogen to the nation?s list of cancer-causing agents.
Recent revelations that Wyeth directed DesignWrite medical ghostwriters to deliberately deemphasize the links between synthetic hormone replacement therapies and breast cancer in published medical journals are bringing experts in the field of BHRT to answer the question of the purpose for manipulating this data.
?There is big money at stake,? says Randolph. ?Prior to the WHI findings being made public in 2002, the Premarin-family of products was a 2.2 billion dollar pipeline.?
Since 2002, sales for Wyeth?s Premarin family of products have plummeted 50 percent, and have continued to decline over the last several years.
Research in the U.S. and around the world supports BHRT as the treatment of choice for menopausal symptoms and conditions of hormone imbalance. Studies conducted by Joel Hargrove, M.D. at Vanderbilt Medical University and Abraham Morgentaler, M.D. at Harvard University have found BHRT to be both safe and effective.
?The sad reality is that when marketing gets ahead of medical science, women?s lives are put at risk,? says Randolph.
Resources
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008 Jan:107(1):103-111.
Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989 Apr;73(4):606-12.
Holtorf K. The Bioidentical Hormone Debate: Are Bioidentical Hormones (Estradiol, Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy? Postgrad Med 2009;121(1):1-13.
James G, Randolph CW. From Hormone Hell to Hormone Well. Deerfield Beach: Health Communications Inc., 2009.
Morgentaler A. Testosterone for Life. New York: McGraw-Hill, 2009.
###
Find More Alzheimer Disease Press Releases
Little Silver, NJ (Vocus) September 17, 2010
Web entrepreneur Stan Abrams is pleased to announce the publication of his brand-new website, http://www.MedicalBraceletsOnline.com. Launched in July, the online business was developed to deliver a premium selection of medical identification jewelry to those with significant medical conditions or ailments.
?These ID tags are a valuable asset to any person with a significant medical condition or ailment. It?s a way to communicate with first responders in an emergency situation if you happen to be unconscious or vocally paralyzed,? Abrams said. ?Medical ID jewelry saves lives by ensuring proper medical diagnosis and care.?
At MedicalBraceletsOnline.com shoppers are invited to browse a delightful collection of medical identification jewelry. Choose from a vast assortment of styles ? in options for men, women and children ? that include medical ID bracelets, medical ID pendants and charms, medical ID dog tags as well as medical ID watches and wristbands.
?Although we carry hundreds of styles to choose from, the ordering process couldn?t be easier,? Abrams said. ?Simply select the style of your choice and then specify what you?d like the jewelry to say; the purchasing form walks you through step by step.?
After a satisfying career in the corporate and education worlds, Abrams was looking for another way to give back to the community. The concept of the medical ID jewelry is a great way to help people who might be in trouble and prevents more trouble for the victim, explained Abrams.
To learn more about the many benefits of medical ID jewelry, visit the website?s new blog, http://www.MedicalBraceletsInfo.com. This social platform serves as an informational counterpart to the website and will be used to provide insightful tidbits about common medical conditions, such as Alzheimer?s disease, diabetes and allergies, as well as current medical research and testing that may help to improve such conditions.
MedicalBraceletsOnline.com, eliminating preventable medical dilemmas worldwide!
About the Company:
MedicalBraceletsOnline.com ? a division of Sunnycrest Global Associates ? is owned and operated by web entrepreneur Stan Abrams. Since 1892, the Abrams family has proudly served the community with a family-owned jewelry business.
Stan Abrams
http://www.MedicalBraceletsOnline.com
(732) 360-7074
iePlexus, Inc.
http://www.iePlexus.com
###
Chantilly, VA (PRWEB) November 30, 2011
Capture Billing & Consulting, Inc., a medical billing company located in South Riding, Virginia, will begin the first semester of 2012 with a fast paced two part class on medical billing, medical coding and collections at Northern Virginia Community College (NVCC), Loudoun Campus in Sterling, Virginia.
NVCC’s “Medical Billing, Coding, and Collections” class will be taught by Katie Jennings. Katie?s experience as a nurse and medical biller has given her the knowledge and insight into both the medical and business aspects of healthcare. Katie’s familiarity with diagnosis codes and insurance companies? claims processes has helped influence the design of the class.
“This class is a great introduction into the medical billing field. I cover all aspects involved in medical billing as well as the medical billing process from beginning to end,” says Katie.
Part one of the two part class consists of lecture and theory. A few of the topics that will be covered in the class are claim preparation, documentation, reimbursements, and collections.
Part two of the class will be a hands-on computerized class. Participants will learn about data entry, claim adjustments, write-offs as well as other topics, with an introduction to medical billing software and management. The class will also review real life billing situations.
Part one and Part two of the program both consist of four sessions each. They will help students prepare to enter the medical billing field as well as those who would like a career change. As medical billing standards change and become more complicated medical offices and medical billing companies will be seeking qualified individuals to manage the billing process.
To learn more about these and other medical billing course please visit:
Part One: http://www.nvcc.edu/wdce/loudoun/courses/classinfo.asp?ID=HLTH+1745
Part Two: http://www.nvcc.edu/wdce/loudoun/courses/classinfo.asp?ID=HLTH+1746
http://www.nvcc.edu/wdce/loudoun/courses/alphalist.asp
ABOUT CAPTURE BILLING
Capture Billing and Consulting, Inc., a leader in the outsourced medical billing services industry, offers one of the most cost effective outsourcing solutions to healthcare professionals available. By eliminating the need of an in-house medical billing staff, Capture Billing’s staff of expert medical billers and certified professional coders help to increase physician reimbursement by improving collection rates and ensuring proper ICD-9 and CPT coding. Practicing physician and CEO, Dr. John D. Farrell, Jr., formed Capture Billing in 2004 as the answer to one of the largest concerns physicians face today, how to receive proper insurance reimbursement for services they provided.
CONTACT INFORMATION
Capture Billing & Consulting Inc.
25055 Riding Plaza, Suite 160
South Riding, VA 20152
(703) 327-1800
Contact: Manny Oliverez
Website: http://www.CaptureBilling.com
# # #
Yokneam, Israel (PRWEB) January 11, 2011
Neuronix Medical announced today that it has received final approval from Beth Israel Deaconess Medical Center (BIDMC), Boston MA, a teaching hospital of Harvard Medical school, to initiate recruitment for its study titled ?Effects of a Combined TMS Stimulation and Cognitive Training in Alzheimer Patients: A Single-Center, Randomized, Double-Blind, Placebo Controlled Study?. The project is expected to start immediately and recruit between 12 to 16 patients, and to employ Neuronix NICE (Non Invasive Cortical Enhancer) for treatment of Alzheimer patients.
?We are very happy to have a prestigious institute such as BIDMC join our growing list of study sites, which already includes leading institutes in Israel and in Europe.? said Eyal Baror, CEO of Neuronix Medical, ?This milestone marks the initiation of our clinical activities in the US, and constitutes a vote of confidence in the promise that the NICE technology has already shown?.
?We have been impressed by the results of prior clinical trials using the NICE system in patients with Alzheimer’s Disease. We feel that such exciting findings warrant further research and running a study at BIDMC is the logical next step.? said Prof. Alvaro Pascual-Leone, Professor of Neurology at Harvard Medical School, and Director of the Berenson-Allen Center of Noninvasive Brain Stimulation. ?Despite a lot of research, Alzheimer?s Disease still presents a huge unmet medical need, and new ideas for treatment which show such promise are very rare indeed. In this study we expect to learn a lot more on the mechanism of action of the technology, and will contribute further findings on the efficacy of the NICE system ?.
About Neuronix Medical
Founded in 2008, Neuronix Medical?s mission is to find a method for modifying the course of treatment of Alzheimer Disease (AD), and thus provide long-term improvement in the quality of life for patients. Led by a highly motivated management team, and supported by key opinion leaders in the field, Neuronix holds all the basic elements for becoming a leading medical device company, and fulfilling its vision to provide relief for millions of AD patients worldwide. The company?s solution, NICE?, is based on a novel, patent pending technology, using stimulation of affected brain regions concurrently interlaced with cognitive training, directed at specific brain regions affected by the disease. The stimulation induces LTP (Long Term Potentiation), which is associated with learning and memory processes, and results in a measurable cognitive improvement after just a few weeks of treatment. For more information visit http://www.neuronixmedical.com.
About BIDMC
The mission of the Beth Israel Deaconess Medical Center (http://www.bidmc.org) is to serve our patients compassionately and effectively, and to create a healthy future for them and their families. BIDMC?s mission is supported by our commitment to personalized, excellent care for our patients; a workforce committed to individual accountability, mutual respect and collaboration; and a commitment to maintaining our financial health. Critical to our success is the partnership between the medical center and its physicians. It is this partnership that allows the medical center to carry out its mission of teaching, research and clinical care. BIDMC?s partnership with Harvard Medical School and its role as a major Harvard teaching hospital strengthen its ability to train, teach and create new knowledge. BIDMC?s is committed to recruiting the best physicians, scientists, nurses and others to support these activities.
###
Find More Alzheimer Disease Press Releases
Washington, DC (PRWEB) March 23, 2011
Today, in a briefing on Capitol Hill, the Alliance for Aging Research released a new volume of The Silver Book
(Vocus/PRWEB) March 24, 2011
Devra Lee Davis, PhD, MPH, award-winning author and President of Environmental Health Trust (EHT), will be lecturing on cell phone safety at NYU Langone Medical Center, Smilow 1st Floor Seminar Room, 550 First Avenue (at 31st Street), New York, NY on Tuesday, April 12 from 6:00 pm to 7:30 pm. Admission is free to the public.
Lasne, Belgium (PRWEB) October 21, 2011
The days of slow, disorganized clinical trials and isolated silos of information are finally over. clin360 is a new content management system (CMS) for the healthcare market that will forever change the way we carry out and even think about clinical trials. The pharmaceutical industry, research organizations, and healthcare professionals alike are sure to appreciate the convenience and flexibility of this ingenious platform, which acts as a central hub for sites, doctors, CRAs, and anybody else involved ? or even merely interested ? in any particular trial. And more importantly, vital clinical trials involving potentially life-saving technology will proceed on a more timely basis.
clin360 is described in a dedicated website: http://www.clin360.com. For those who visit the site and decide to get hooked up, the great benefits of such a well-thought-out CMS will be immediately evident. Users are going to get a platform which takes all aspects of running a clinical trial and brings them together under one format, making it easily and securely available to anyone involved anywhere in the world, using any type of standard browser. CRAs, investigators, health care professionals, management, and the public alike are going to love the control, visibility and overall access.
In designing this product, the internationally recognized Coligane Group set out with the goals of making trial recruitment easier, and streamlining the monitoring and management of trials by CRAs. Public access to trial progress and general information was another major consideration in its overall design. ?We feel that public education about clinical trials, and streamlining the efficiency of those trials, not only ought to be a moral imperative, but that it really just makes good business sense,? says Olivier Laurent, CEO at Coligane. He explains: ?Getting the public excited about pure research, product development, and/or possible distribution is one of the best marketing strategies out there ? not merely for the subject of your trial, but for your entire brand or institution.?
But, good PR aside, the primary crux of clin360 lies in the process itself. Every aspect of clin360 has been thoroughly tested by seasoned industry professionals, and all of them attest to both the usability and the security of the system. The platform features 5 different levels of secure access: HCP, Investigator, CRA, Manager, and Administrator. Each user has the ability to custom configure the settings in order to prioritize different sources of information, as well as to disseminate info to appropriate parties. The platform offers SMTP services (e-mail) and hosting, Google analytics activation for HCP, Investigator, Manager and CRA role users, allows multiple languages within its context, and is designed to be user friendly, practical, and useful to practically every member of the study team.
Having developed such a novel, convenient, and innovative product, Coligane is clearly targeting the entire world market. ?Luxembourg has been the first to take on the platform, even before the official launch, but we?re shooting for all corners of the globe?, says Laurent. He continues, ?Our position as a consultancy allows us superior flexibility in both thought and action. For instance, Coligane group will install and configure this core CMS onto our clients? own servers, or we can propose a dedicated hosting plan on our very own data center. We are able to adapt clin360 to each client?s needs, for each and every unique situation.? Coligane seems to have its ducks in a row with clin360? an instantly essential and desirable product, a well-planned marketing strategy, and the prestige of a respected, well-connected research consultancy group will go a long way to ensure great success.
About Coligane Group
Coligane Group is an entrepreneurial consultancy based in Lasne Belgium, specializing in Health Care, Pharmaceutical, and Clinical Research solutions, as well as the Computer and Service Industries in general. Coligane takes a full-spectrum approach to their services, acting as a solid platform for their clients, helping their dreams develop quickly into concrete applications
Follow coligane @coligane
Clin360 on Facebook Like here
###
Related Wellness Press Releases
BOSTON, MA (PRWEB) November 12, 2003
November is National Alzheimers Awareness Month, an opportune time to educate the public about the basics of the disease, the advances in medicine, and the outlook for the future. Harvard Health Publications, the publishing division of Harvard Medical School, has published A Guide to Alzheimers Disease to assist family members, patients, and caregivers in understanding and coping with Alzheimers.
Although a cure has not yet been discovered, early diagnosis has become increasingly important to help delay the worsening of symptoms and allow patients and caregivers to plan for the future. However, reaching an accurate diagnosis can be complicated and uncertain. A Guide to Alzheimers Disease provides an informative foundation that not only outlines warning signs and possible risk factors, but also equips readers with specific ways to recognize symptoms.
The report guides readers through the entire diagnosis process from finding a physician to understanding the types of tests performed. By knowing what to expect and how evaluation for Alzheimers is conducted, patients and caregivers will be better prepared to make informed decisions.
While diagnosis can be disheartening, A Guide to Alzheimers Disease offers a hopeful look for the growing population affected by the disease. The report covers: